Ruolo dei bloccanti del recettore piastrinico GP IIb/IIIa nella cardiologia clinica

Translated title of the contribution: Role of GP IIb/IIIa blockers in cardiovascular medicine

Marco L. Rossi, Piera Angelica Merlini

Research output: Contribution to journalArticlepeer-review


Platelet aggregation and thrombosis play a key role in the pathogenesis of unstable coronary syndromes and their ischemic complication. The platelet glycoprotein (GP) IIb/IIIa receptor represents the final common pathway leading to platelet aggregation. In the last 10 years agents that block the GP IIb/IIIa receptor has been developped and tested on a large number of large-scale, randomized trials showing that these drugs, particularly when administered in intravenous form, reduce morbidity and death in patients with acute coronary syndromes and those urdengoing percutaneous intervention.

Translated title of the contributionRole of GP IIb/IIIa blockers in cardiovascular medicine
Original languageItalian
Pages (from-to)440-443
Number of pages4
JournalRecenti Progressi in Medicina
Issue number10
Publication statusPublished - Oct 2003

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Role of GP IIb/IIIa blockers in cardiovascular medicine'. Together they form a unique fingerprint.

Cite this